Compare Sterling Biotech with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs DIVIS LABORATORIES - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH DIVIS LABORATORIES STERLING BIOTECH/
DIVIS LABORATORIES
 
P/E (TTM) x -0.4 31.5 - View Chart
P/BV x 0.0 7.1 0.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 STERLING BIOTECH   DIVIS LABORATORIES
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
DIVIS LABORATORIES
Mar-18
STERLING BIOTECH/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs111,142 0.9%   
Low Rs3533 0.6%   
Sales per share (Unadj.) Rs26.8146.6 18.3%  
Earnings per share (Unadj.) Rs-15.033.0 -45.3%  
Cash flow per share (Unadj.) Rs-5.538.4 -14.2%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs54.9222.8 24.6%  
Shares outstanding (eoy) m267.87265.47 100.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.7 4.5%   
Avg P/E ratio x-0.525.3 -1.8%  
P/CF ratio (eoy) x-1.321.8 -5.8%  
Price / Book Value ratio x0.13.8 3.4%  
Dividend payout %030.3 0.0%   
Avg Mkt Cap Rs m1,862222,318 0.8%   
No. of employees `0001.410.8 12.6%   
Total wages/salary Rs m5474,561 12.0%   
Avg. sales/employee Rs Th5,303.33,616.0 146.7%   
Avg. wages/employee Rs Th403.8423.8 95.3%   
Avg. net profit/employee Rs Th-2,959.0814.9 -363.1%   
INCOME DATA
Net Sales Rs m7,18138,915 18.5%  
Other income Rs m431,134 3.8%   
Total revenues Rs m7,22340,049 18.0%   
Gross profit Rs m94712,617 7.5%  
Depreciation Rs m2,5431,425 178.5%   
Interest Rs m4,37713 32,910.5%   
Profit before tax Rs m-5,93112,313 -48.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9243,543 -54.3%   
Profit after tax Rs m-4,0078,770 -45.7%  
Gross profit margin %13.232.4 40.7%  
Effective tax rate %32.428.8 112.8%   
Net profit margin %-55.822.5 -247.6%  
BALANCE SHEET DATA
Current assets Rs m14,33545,351 31.6%   
Current liabilities Rs m49,8096,507 765.4%   
Net working cap to sales %-494.099.8 -494.9%  
Current ratio x0.37.0 4.1%  
Inventory Days Days403127 318.4%  
Debtors Days Days17195 179.4%  
Net fixed assets Rs m55,43221,160 262.0%   
Share capital Rs m268531 50.5%   
"Free" reserves Rs m13,93558,625 23.8%   
Net worth Rs m14,70159,156 24.9%   
Long term debt Rs m9,4780-   
Total assets Rs m73,98867,832 109.1%  
Interest coverage x-0.4926.8 -0.0%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.10.6 16.9%   
Return on assets %0.512.9 3.9%  
Return on equity %-27.314.8 -183.8%  
Return on capital %-6.420.8 -30.8%  
Exports to sales %25.90-   
Imports to sales %0.221.8 0.8%   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m128,485 0.1%   
Fx inflow Rs m1,86032,359 5.7%   
Fx outflow Rs m259,042 0.3%   
Net fx Rs m1,83523,317 7.9%   
CASH FLOW
From Operations Rs m1,7197,759 22.2%  
From Investments Rs m-3,148-4,783 65.8%  
From Financial Activity Rs m1,426-3,142 -45.4%  
Net Cashflow Rs m-3-166 2.0%  

Share Holding

Indian Promoters % 33.9 52.0 65.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 11.8 -  
FIIs % 9.9 19.0 52.1%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 17.2 228.5%  
Shareholders   21,482 31,796 67.6%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   ORCHID PHARMA LTD  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS